Marc Arthur Loko
- Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohortMarc Arthur Loko
Universite Bordeaux, ISPED, Centre INSERM U897 Epidemiologie Biostatistique, F 33000 Bordeaux, France
Antivir Ther 17:1335-43. 2012..The aim of this study was to describe changes in repeated liver stiffness (LS) measurements and to assess the determinants of increase in LS in HIV-HCV-coinfected patients...
- Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)Dominique Salmon-Ceron
Unité de maladies infectieuses, Pôle Médecine, Hopital Cochin, Paris, France
BMC Health Serv Res 12:59. 2012..Treatment for the hepatitis C virus (HCV) may be delayed significantly in HIV/HCV co-infected patients. Our study aims at identifying the correlates of access to HCV treatment in this population...
- The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010Marc Arthur Loko
INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
BMC Infect Dis 10:303. 2010..The ANRS CO 13 HEPAVIH cohort was set up to explore these critical questions.To describe the cohort aims and organization, monitoring and data collection procedures, baseline characteristics, as well as follow-up findings to date...
- Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?Pascale Trimoulet
Laboratoire de Microbiologie Fondamentale et Pathogénicité UMR 5234, Centre Hospitalier Universitaire CHU et Université Bordeaux Ségalen, Hopital Pellegrin, Bordeaux, France
J Virol Methods 181:131-3. 2012..0001). This study shows that using the same assay in multicenter trials and cohorts is still relevant due to inter-assay differences observed in HCV plasma load measurements...
- Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine CohortDidier Neau
Fédération des Maladies Infectieuses et Tropicales, Centre Hospitalo Universitaire, Hopital Pellegrin, Bordeaux, France
J Acquir Immune Defic Syndr 45:168-73. 2007..The prevalence and factors associated with hepatic steatosis are not well defined in HCV-HIV-coinfected patients...
- Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort)Fabienne Marcellin
INSERM, UMR912 SESSTIM, Marseille, France
Addiction 108:1250-8. 2013..Studying alcohol abuse impact, as measured by physicians' perceptions and patients' self-reports, on HIV virological rebound among patients chronically co-infected with HIV and hepatitis C virus (HCV)...
- Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohortMarc Arthur Loko
INSERM, U593, Bordeaux, France
Am J Gastroenterol 103:1973-80. 2008..Although an increasing number of noninvasive fibrosis markers are available in HCV-monoinfected patients, data on the performance of these tests in HIV-HCV-coinfected patients are lacking...